GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety
and efficacy of GVD±R (gemcitabine, oral vinorelbine and doxorubicin liposome, with or
without rituximab) regimen for autologous hematopoietic stem cell
transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell
lymphoma.